ST Premium
For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.
Ready to Win Big?
Try Now for Just $1!NeuroMetrix, Inc. (NURO) stock declined over -0.02%, trading at $4.37 on NASDAQ, down from the previous close of $4.37. The stock opened at $4.39, fluctuating between $4.37 and $4.39 in the recent session.
NeuroMetrix, Inc., a healthcare company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, China, the Middle East, and Mexico. Its primary marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system, a platform for the performance of nerve conduction studies. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.
Employees | 26 |
Beta | 2.17 |
Sales or Revenue | $5.90M |
5Y Sales Change% | -0.734% |
Fiscal Year Ends | December |
Sector | Healthcare |
Industry | Medical - Devices |
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com